ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02275533
Recruitment Status : Recruiting
First Posted : October 27, 2014
Last Update Posted : June 6, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 28, 2019
  Study Completion Date : No date given